Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.

Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A.

J Neurooncol. 2019 Sep;144(3):553-562. doi: 10.1007/s11060-019-03257-1. Epub 2019 Aug 3.

PMID:
31377920
2.

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.

Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB.

J Neurooncol. 2019 Sep;144(2):403-407. doi: 10.1007/s11060-019-03243-7. Epub 2019 Jul 19.

PMID:
31325145
3.

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.

Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF.

Neuro Oncol. 2018 Oct 9;20(11):1525-1535. doi: 10.1093/neuonc/noy064.

4.

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053.

5.

Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.

Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W.

Neuro Oncol. 2018 Mar 27;20(4):557-566. doi: 10.1093/neuonc/nox162.

6.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

7.

CNS Anticancer Drug Discovery and Development: 2016 conference insights.

Levin VA, Abrey LE, Heffron TP, Tonge PJ, Dar AC, Weiss WA, Gallo JM.

CNS Oncol. 2017 Jul 18. doi: 10.2217/cns-2017-0014. [Epub ahead of print]

8.

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.

Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF.

Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27.

9.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

10.

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF.

Neuro Oncol. 2017 Jan;19(1):89-98. doi: 10.1093/neuonc/now187. Epub 2016 Aug 31.

11.

Reply to T.J. Kruser et al.

Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T.

J Clin Oncol. 2016 Apr 10;34(11):1282-3. doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16. No abstract available.

PMID:
26884575
12.

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY.

Clin Cancer Res. 2016 Feb 1;22(3):575-81. doi: 10.1158/1078-0432.CCR-14-3040. Epub 2015 Oct 21.

13.

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.

Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY.

Cancer. 2015 Dec 1;121(23):4165-72. doi: 10.1002/cncr.29636. Epub 2015 Aug 26.

14.

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C.

J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29. Erratum in: J Clin Oncol. 2016 Sep 1;34(25):3113.

15.

Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Nayak L, Panageas KS, Reiner AS, Huse JT, Pentsova E, Braunthal SG, Abrey LE, DeAngelis LM, Lassman AB.

J Neurooncol. 2015 May;123(1):129-34. doi: 10.1007/s11060-015-1771-8. Epub 2015 Apr 29.

16.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS.

Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7.

17.

Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.

Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT.

Clin Cancer Res. 2014 Oct 1;20(19):5023-31. doi: 10.1158/1078-0432.CCR-14-0822. Epub 2014 Aug 8.

18.

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A.

Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.

19.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

20.

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A.

J Clin Oncol. 2013 Nov 1;31(31):3971-9. doi: 10.1200/JCO.2013.50.4910. Epub 2013 Oct 7.

21.

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF.

Curr Neurol Neurosci Rep. 2013 May;13(5):347. doi: 10.1007/s11910-013-0347-2. Review.

22.

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.

Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.

23.

A phase II trial of oral gimatecan for recurrent glioblastoma.

Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F.

J Neurooncol. 2013 Feb;111(3):347-53. doi: 10.1007/s11060-012-1023-0. Epub 2012 Dec 12.

PMID:
23232808
24.

Post-treatment T1 shortening in primary CNS lymphoma.

Karimi S, Hatzoglou V, Punia V, Partovi S, Abrey LE, Deangelis LM.

J Neurooncol. 2013 Jan;111(1):25-31. doi: 10.1007/s11060-012-0984-3. Epub 2012 Oct 17.

PMID:
23073601
25.

Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.

Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE, Gutin PH.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):636-42. doi: 10.1016/j.ijrobp.2012.05.031. Epub 2012 Jul 3.

PMID:
22765876
26.

Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2012 Jun;14(6):761-7. doi: 10.1093/neuonc/nos065. Epub 2012 May 31.

27.

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.

Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A; North American Brain Tumor Consortium.

Leuk Lymphoma. 2013 Jan;54(1):58-61. doi: 10.3109/10428194.2012.698736. Epub 2012 Jul 9.

28.

Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older.

Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey LE, DeAngelis LM, Shih JH, Iwamoto FM.

Cancer. 2012 Nov 15;118(22):5595-600. doi: 10.1002/cncr.27570. Epub 2012 Apr 19.

29.

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.

Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T.

J Neurooncol. 2012 Jul;108(3):491-8. doi: 10.1007/s11060-012-0847-y. Epub 2012 Mar 18.

30.

The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.

Abrey LE.

J Neurooncol. 2012 Jun;108(2):285-90. doi: 10.1007/s11060-012-0807-6. Epub 2012 Feb 17. Review.

PMID:
22350376
31.

Cognitive functions in primary CNS lymphoma after single or combined modality regimens.

Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT.

Neuro Oncol. 2012 Jan;14(1):101-8. doi: 10.1093/neuonc/nor186. Epub 2011 Oct 19.

32.

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.

Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10.

33.

Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent glioma.

Ballangrud AM, Lymberis S, Thakur SB, Karimi S, Huang W, Abrey LE, Beal K, Iwamoto FM, Brennan C, Gutin PH, Chang J.

Med Phys. 2011 May;38(5):2724-30.

PMID:
21776809
34.

Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A.

J Neurooncol. 2011 Dec;105(3):607-12. doi: 10.1007/s11060-011-0628-z. Epub 2011 Jun 28.

PMID:
21710351
35.

Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.

Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A.

Leuk Lymphoma. 2011 Oct;52(10):1891-7. doi: 10.3109/10428194.2011.585527. Epub 2011 Jun 24.

PMID:
21699456
36.

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS.

Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040.

37.

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS.

Neuro Oncol. 2011 Jun;13(6):660-8. doi: 10.1093/neuonc/nor024. Epub 2011 May 9.

38.

YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.

Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A.

Ann Neurol. 2011 Jul;70(1):163-9. doi: 10.1002/ana.22360. Epub 2011 Mar 9.

PMID:
21391238
39.

Late relapse in primary central nervous system lymphoma: clonal persistence.

Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM.

Neuro Oncol. 2011 May;13(5):525-9. doi: 10.1093/neuonc/nor014. Epub 2011 Mar 3.

40.

Advances in primary CNS lymphoma: randomized clinical trials of chemotherapy and whole-brain radiotherapy.

Abrey LE.

Curr Neurol Neurosci Rep. 2011 Jun;11(3):243-5. doi: 10.1007/s11910-011-0183-1. No abstract available.

PMID:
21271308
41.

Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Ghesquieres H, Silver M, Betensky RA, Batchelor T.

Clin Cancer Res. 2011 Jan 15;17(2):346-52. doi: 10.1158/1078-0432.CCR-10-1161. Epub 2011 Jan 11.

42.
43.

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS.

Oncologist. 2010;15(12):1329-34. doi: 10.1634/theoncologist.2010-0105. Epub 2010 Dec 8.

44.

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS.

Neuro Oncol. 2011 Jan;13(1):143-51. doi: 10.1093/neuonc/noq151. Epub 2010 Nov 17.

45.

Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas.

Morris PG, Abrey LE.

Target Oncol. 2010 Sep;5(3):193-200. doi: 10.1007/s11523-010-0160-7. Epub 2010 Sep 16. Review.

PMID:
20844972
46.

Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE.

Cancer. 2010 Oct 1;116(19):4605-12. doi: 10.1002/cncr.25363.

47.

Hematology. Individualized methotrexate dosing in primary CNS lymphoma.

Abrey LE.

Nat Rev Clin Oncol. 2010 Jun;7(6):306-7. doi: 10.1038/nrclinonc.2010.66.

PMID:
20517339
48.

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA.

Neuro Oncol. 2010 Aug;12(8):855-61. doi: 10.1093/neuonc/noq025. Epub 2010 Mar 3.

49.

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2010 Jan;12(1):95-103. doi: 10.1093/neuonc/nop015. Epub 2009 Dec 14.

50.

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2010 Jan;12(1):87-94. doi: 10.1093/neuonc/nop017. Epub 2009 Dec 14.

Supplemental Content

Loading ...
Support Center